SUZ12 depletion suppresses the proliferation of gastric cancer cells

Cellular Physiology and Biochemistry

Volumn 31, Issue 6, 2013, Pages 778-784

  Cui, Yingjun ^a   Chen, Jie ^b   He, Zhixian ^c   Xiao, Yongtao ^b  

^a YANTAISHAN HOSPITAL   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c NANTONG MEDICAL COLLEGE   (China)

Author keywords

Epigenetic; Gastric cancer; MicroRNA; Proliferation; SUZ12

Indexed keywords

PROTEIN P27; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR SUZ12; UNCLASSIFIED DRUG;

ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; GASTRIC CANCER CELL LINE; HUMAN; HUMAN CELL; LUCIFERASE ASSAY; PRIORITY JOURNAL; PROTEIN DEPLETION; RNA INTERFERENCE; S PHASE CELL CYCLE CHECKPOINT; STOMACH CANCER; WESTERN BLOTTING;

EID: 84878349348     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000350095     Document Type: Article

References (23)

1. Pasini D, Bracken AP, Jensen MR, Lazzerini Denchi E, Helin K: Suz12 is essential for mouse development and for ezh2 histone methyltransferase activity. EMBO J 2004;23:4061-4071.
2. Cao R, Zhang Y: Suz12 is required for both the histone methyltransferase activity and the silencing function of the eed-ezh2 complex. Mol Cell 2004;15:57-67.
3. Li H, Cai Q, Wu H, Vathipadiekal V, Dobbin ZC, Li T, Hua X, Landen CN, Birrer MJ, Sanchez-Beato M, Zhang R: Suz12 promotes human epithelial ovarian cancer by suppressing apoptosis via silencing hrk. Mol Cancer Res 2012;10:1462-1472.
4. Iliopoulos D, Lindahl-Allen M, Polytarchou C, Hirsch HA, Tsichlis PN, Struhl K: Loss of mir-200 inhibition of suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells. Mol Cell 2010;39:761-772.
5. Martin-Perez D, Sanchez E, Maestre L, Suela J, Vargiu P, Di Lisio L, Martinez N, Alves J, Piris MA, Sanchez-Beato M: Deregulated expression of the polycomb-group protein suz12 target genes characterizes mantle cell lymphoma. Am J Pathol 2010;177:930-942.
6. Li H, Ma X, Wang J, Koontz J, Nucci M, Sklar J: Effects of rearrangement and allelic exclusion of jjaz1/suz12 on cell proliferation and survival. Proc Natl Acad Sci U S A 2007;104:20001-20006.
7. Hinz S, Kempkensteffen C, Christoph F, Krause H, Schrader M, Schostak M, Miller K, Weikert S: Expression parameters of the polycomb group proteins bmi1, suz12, ring1 and cbx7 in urothelial carcinoma of the bladder and their prognostic relevance. Tumour Biol 2008;29:323-329.
8. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
9. Parkin DM: Epidemiology of cancer: Global patterns and trends. Toxicol Lett1998;102-103:227-234.
10. He LJ, Cai MY, Xu GL, Li JJ, Weng ZJ, Xu DZ, Luo GY, Zhu SL, Xie D: Prognostic significance of overexpression of ezh2 and h3k27me3 proteins in gastric cancer. Asian Pac J Cancer Prev 2012;13:3173-3178.
11. Carvalho J, van Grieken NC, Pereira PM, Sousa S, Tijssen M, Buffart TE, Diosdado B, Grabsch H, Santos MA, Meijer G, Seruca R, Carvalho B, Oliveira C: Lack of microrna-101 causes e-cadherin functional deregulation through ezh2 up-regulation in intestinal gastric cancer. J Pathol 2012;228:31-44.
12. Mattioli E, Vogiatzi P, Sun A, Abbadessa G, Angeloni G, D'Ugo D, Trani D, Gaughan JP, Vecchio FM, Cevenini G, Persiani R, Giordano A, Claudio PP: Immunohistochemical analysis of prb2/p130, vegf, ezh2, p53, p16(ink4a), p27(kip1), p21(waf1), ki-67 expression patterns in gastric cancer. J Cell Physiol 2007;210:183-191.
13. Shinozaki A, Sakatani T, Ushiku T, Hino R, Isogai M, Ishikawa S, Uozaki H, Takada K, Fukayama M: Downregulation of microrna-200 in ebv-associated gastric carcinoma. Cancer Res 2010;70:4719-4727.
14. Iredale JP, Benyon RC, Pickering J, McCullen M, Northrop M, Pawley S, Hovell C, Arthur MJ: Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest 1998;102:538-549.
15. Philipp-Staheli J, Payne SR, Kemp CJ: P27(kip1): Regulation and function of a haploinsufficient tumor suppressor and its misregulation in cancer. Exp Cell Res 2001;264:148-168.
16. Zhang H, Zhao M, Lv Z, Zhang X, Qin X, Wang H, Wang S, Su J, Lv X, Liu H, Du W, Zhou W, Chen X, Fei K: Mir-138 inhibits tumor growth through repression of ezh2 in non-small cell lung cancer. Cell Physiol Biochem 2013;31:56-65.
17. Kikuchi J, Takashina T, Kinoshita I, Kikuchi E, Shimizu Y, Sakakibara-Konishi J, Oizumi S, Marquez VE, Nishimura M, Dosaka-Akita H: Epigenetic therapy with 3-deazaneplanocin a, an inhibitor of the histone methyltransferase ezh2, inhibits growth of non-small cell lung cancer cells. Lung Cancer 2012;78:138-143.
18. Xia H, Yu CH, Zhang Y, Yu J, Li J, Zhang W, Zhang B, Li Y, Guo N: Ezh2 silencing with rnai enhances irradiation-induced inhibition of human lung cancer growth in vitro and in vivo. Oncol Lett 2012;4:135-140.
19. Chen Y, Xie D, Yin Li W, Man Cheung C, Yao H, Chan CY, Xu FP, Liu YH, Sung JJ, Kung HF: Rnai targeting ezh2 inhibits tumor growth and liver metastasis of pancreatic cancer in vivo. Cancer Lett 2010;297:109-116.
20. Karanikolas BD, Figueiredo ML, Wu L: Comprehensive evaluation of the role of ezh2 in the growth, invasion, and aggression of a panel of prostate cancer cell lines. Prostate 2010;70:675-688.
21. Ougolkov AV, Bilim VN, Billadeau DD: Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2. Clin Cancer Res 2008;14:6790-6796.
22. Korpal M, Lee ES, Hu G, Kang Y: The mir-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of e-cadherin transcriptional repressors zeb1 and zeb2. J Biol Chem 2008;283:14910-14914.
23. Park SM, Gaur AB, Lengyel E, Peter ME: The mir-200 family determines the epithelial phenotype of cancer cells by targeting the e-cadherin repressors zeb1 and zeb2. Genes Dev 2008;22:894-907.